# A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

> **NCT02174510** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma (Suzhou) Co., Ltd.** · enrollment: 37 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** 20mg lurasidone
- **DRUG:** 40mg lurasidone
- **DRUG:** 80mg lurasidone
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02174510
- **Lead sponsor:** Sumitomo Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174510, "A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02174510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*